Insights

Gathering insights about ADC…

Similar companies to ADC

ADC Tech Stack

Media & News

Agree Realty Declares Monthly Common and Preferred Dividends
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.262 per common share. The monthly dividend reflects an annualized dividend amount of $3.144 per common share, representing a 3.6% increase over the annualized dividend amount of $3.036 per common share from the fourth quarter of 2024. The dividend is payable December 12, 2025 to stockholder.
Nov 11, 2025 | www.businesswire.com
Targeting Adhesion Molecules With ADC's: The Bet Of CytomX
CytomX (CTMX) is advancing its ADC candidate CX-2051 in the oncological field. CX-2051 shows an impressive response rate and improved progression-free survival in heavily pretreated colorectal cancer patients, outperforming current therapies. Investment in CTMX is high risk and binary, but promising science and early clinical data support a speculative Buy for risk-tolerant investors.
Nov 11, 2025 | seekingalpha.com
Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
Data presented at the 40 th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor immunity through multiple mechanisms Treatment with a Trastuzumab-PH1 ADC monotherapy drove macrophages to polarize into an anti-tumor/inflammatory state and caused expansion of B cell clones and subsequent IgM antibodies When combined with anti-PD1 therapy, additional effects included expansion of Gamma-Delta T cell clones demonstrating that the combined regimen drives innate, adaptive, and humoral immunity against the tumor In preclinical experiments, the combination of Trastuzumab PH1 + anti-PD1 outperforms the combination of Kadcyla ® + anti-PD1 with a statistically significantly greater rate of Complete Responses (74% v 42%, p
Nov 10, 2025 | www.globenewswire.com
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026 Updated data from Phase 2 IIT of ZYNLONTA® plus rituximab in patients with r/r follicular lymphoma presented at the 22nd International Workshop on Non-Hodgkin Lymphoma Recent financing supports expansion of ZYNLONTA in anticipation of 2L+ DLBCL launch with strengthened balance sheet relative to previously disclosed cash runway into 2028 LAUSANNE, Switzerland , Nov. 10, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2025, and provided operational updates. "The successful completion of our most recent PIPE financing strengthens our balance sheet and provides the resources to further invest in ZYNLONTA ® as we anticipate advancing into earlier lines of therapy for DLBCL and into indolent lymphomas," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
Nov 10, 2025 | www.prnewswire.com
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or unresectable solid tumors. DS3610 is an investigational STING agonist antibody drug conjugate (ADC) containing an immunomodulatory payload discovered by Daiichi Sankyo (TSE:4568). Despite the availability of various cancer immunotherapies, there remains an unmet need for novel treatment options with distinct mechanisms of act.
Nov 10, 2025 | www.businesswire.com
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce the successful presentation of new data on its proprietary Accum® platform at the 16th World ADC Conference in San Diego, USA (November 4-5, 2025). The presentation generated exceptional interest from both the scientific and industry communities, with attendees continuing discussions around Defence's poster long after the official session concluded.
Nov 06, 2025 | www.newsfilecorp.com
Agree Realty Corporation (NYSE:ADC) Receives Average Recommendation of “Moderate Buy” from Brokerages
Agree Realty Corporation (NYSE: ADC - Get Free Report) has been given an average recommendation of "Moderate Buy" by the sixteen ratings firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month price target among
Nov 05, 2025 | www.defenseworld.net

ADC's Email Address Formats

ADC uses at least 1 format(s):

ADC Email Formats	Example	Percentage
First.Last@adc.com	John.Doe@adc.com	91%
First_Last@adc.com	John_Doe@adc.com	6%
Last.First@adc.com	Doe.John@adc.com	2%
FLast@adc.com	JDoe@adc.com	1%

Frequently Asked Questions

Where is ADC's headquarters located?

ADC's main headquarters is located at 13625 Technology Drive, Eden Prairie, Minnesota 55344, US. The company has employees across 6 continents, including North AmericaAsiaEurope.

What is ADC's phone number?

You can contact ADC's main corporate office by phone at

+1-952-938-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is ADC's stock symbol?

ADC is a publicly traded company; the company's stock symbol is ADC.

What is ADC's official website and social media links?

ADC's official website is adc.com and has social profiles on LinkedIn.

How much revenue does ADC generate?

As of October 2025, ADC's annual revenue is estimated to be $5B.

What is ADC's SIC code NAICS code?

ADC's SIC code is 5995 - Optical Goods Stores NAICS code is 517 - Telecommunications.

How many employees does ADC have currently?

As of October 2025, ADC has approximately 5K employees across 6 continents, including North AmericaAsiaEurope. Key team members include CEO: A. M.CPO: N. N.Chief Financial Officer: G. H.. Explore ADC's employee directory with LeadIQ.

What industry does ADC belong to?

ADC operates in the Telecommunications industry.

What is ADC's email format?

ADC's email format typically follows the pattern of First.Last@adc.com. Find more ADC email formats with LeadIQ.

When was ADC founded?

ADC was founded in 1935.

ADC

TelecommunicationsUnited States5001-10000 Employees

We help the world communicate, supplying network equipment, software solutions, and integration services for broadband, multiservice networks that deliver data, video, and voice communications over telephone, cable television, Internet, broadcast, wireless, and enterprise networks.

(from www.adc.com)